rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Werewolf Therapeutics, Inc.

HOWL · Nasdaq

Health CareBiotechnologyIn trend

HOWL stood above a rising 150-day average in 9 of the last 52 weekly readings, including each of the last 7 weeks. It is 56.3% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
7 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$11.0M
Officials’ trades on record
0
Institutions holding
43 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$3.2M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months156
Buyers · sellers0 · 12
WhoDidSharesTraded
Luke EvninDirectorsold107,429at $0.317 Jul 2026filed 8 Jul 2026
Luke EvninDirectorsold35,770at $0.326 Jul 2026filed 8 Jul 2026
Luke EvninDirectorsold157,084at $0.3029 Jun 2026filed 29 Jun 2026
Ra Capital Management, L.p.10% ownersold389,216at $0.3517 Jun 2026filed 22 Jun 2026
Ra Capital Management, L.p.10% ownersold27,695at $0.3517 Jun 2026filed 22 Jun 2026
Ra Capital Management, L.p.10% ownersold139,686at $0.3716 Jun 2026filed 16 Jun 2026
Ra Capital Management, L.p.10% ownersold9,939at $0.3716 Jun 2026filed 16 Jun 2026
Ra Capital Management, L.p.10% ownersold120,216at $0.3915 Jun 2026filed 16 Jun 2026
Ra Capital Management, L.p.10% ownersold8,554at $0.3915 Jun 2026filed 16 Jun 2026
Ra Capital Management, L.p.10% ownersold159,119at $0.4012 Jun 2026filed 16 Jun 2026
Ra Capital Management, L.p.10% ownersold11,322at $0.4012 Jun 2026filed 16 Jun 2026
Ra Capital Management, L.p.10% ownersold245,066at $0.3811 Jun 2026filed 11 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders43-3 on the quarter
New · exited8 · 11
Reported value$3.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RA CAPITAL MANAGEMENT, L.P.reduced · filed 14 Aug 20262,387,744$859K-4,293,563−64.3%
Balyasny Asset Management L.P.new · filed 14 Aug 20261,790,089$644K+1,790,089
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 20261,217,976$438K00.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026674,632$243K+158,414+30.7%
Lynx1 Capital Management LPunchanged · filed 12 Aug 2026657,786$237K00.0%
SPHERA FUNDS MANAGEMENT LTD.unchanged · filed 14 Aug 2026626,810$226K00.0%
DC Funds, LPunchanged · filed 14 Aug 2026589,102$212K00.0%
Verdad Advisers, LPadded · filed 14 Aug 2026348,709$126K+318,949+1071.7%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026335,815$121K-53,672−13.8%
BANK OF AMERICA CORPadded · filed 14 Aug 2026311,502$112K+46,919+17.7%
31 Mar 2023 – 30 Jun 2026
324864Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Luke Evnin Company insiderDirector · last 7 Jul 20261 · 88
RA CAPITAL MANAGEMENT, L.P. Company insider10% owner · last 17 Jun 20260 · 10
Peter Kolchinsky Company insider10% owner · last 11 Jun 20260 · 3
Mpm Bioimpact Llc Company insiderOther · last 4 Dec 20251 · 6
Mpm Bioventures 2014 (B), L.p. Company insiderOther · last 4 Dec 20250 · 3
Mpm Asset Management Investors Bv2014 Llc Company insider10% owner · last 1 Dec 20250 · 7
Ubs Oncology Impact Fund L.p. Company insider10% owner · last 1 Dec 20250 · 10
Mpm Bioventures 2014 Gp Llc Company insider10% owner · last 25 Nov 20250 · 3
Mpm Oncology Innovations Fund Gp Llc Company insider10% owner · last 25 Nov 20250 · 9
Mpm Bioventures 2014 Llc Company insider10% owner · last 20 Nov 20251 · 12
MPM BioVentures 2014, L.P. Company insider10% owner · last 12 Nov 20250 · 4
Mpm Oncology Innovations Fund Lp Company insider10% owner · last 3 Nov 20250 · 3

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-182%
Debt to equityFY 2025 · to 31 Dec 20251.29×
Interest coverFY 2025 · to 31 Dec 2025-11.50×
Share count trendFY 2025 · to 20 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$57.0M
Free cash flowFY 2025 · to 31 Dec 2025−$60.3M

Analyst forecasts

No analyst forecasts yet.